Microwave ablation offers a promising treatment option for multifocal papillary thyroid cancer

Radiological Society of North AmericaApr 2 2024

In a 10-center study, microwave ablation offered progression free survival rates and fewer complications than surgery in the treatment of a form of thyroid cancer known as papillary thyroid carcinoma (PTC), according to research published today in Radiology, a journal of the Radiological Society of North America (RSNA).

The most common type of thyroid cancer, PTC often presents with multifocality, meaning that two or more bumps or nodules (papillae) are found within the thyroid gland. The occurrence of multifocality within PTC cases is notably frequent, ranging between approximately 23.5% and 60%.

Multifocal PTC is often treated with surgical resection, where all or part of the thyroid is surgically removed. Thyroid surgery is not without side effects. It can impact the patient's quality of life due to factors like scarring, the necessity of lifelong hormone replacement and potential complications, such as permanent hoarseness or impaired thyroid function.

Microwave ablation, a minimally invasive procedure that uses heat to destroy tumors, is currently under preliminary investigation and could be a viable alternative to surgery for some patients.

This study marks the first multicenter comparative analysis between microwave ablation and surgical resection for multifocal papillary thyroid cancer. These findings challenge traditional treatment paradigms and open new avenues for less invasive management strategies."

Ming-An Yu, M.D., senior author, director of interventional medicine at China-Japan Friendship Hospital in Beijing, China

Researchers looked at 775 patients with ultrasound-detected multifocal Stage I PTC treated with microwave ablation or surgery across 10 centers between May 2015 and December 2021. Propensity score matching-;a technique used to compare groups with potentially different baseline characteristics-;was performed, followed by comparisons between the two groups. Propensity score matching helps reduce bias by creating comparable groups, allowing for a more reliable assessment of the treatment effect.

After propensity score matching, 229 patients in the microwave ablation group and 453 patients in the surgical resection group were followed for a median of 20 months (range 12-74 months) and 26 months (range 12-64 months), respectively.

Microwave ablation was associated with similar progression-free survival rates to surgery (5-year: 77.2% vs. 83.1%) but with fewer complications and a greater potential for preserving thyroid function.

Microwave ablation resulted in less blood loss, shorter incision length, and shorter procedure and hospitalization durations. Permanent hoarseness (2.2%) and hypoparathyroidism (4.0%) were encountered only in the surgical resection group.

"Our study has shown that microwave ablation offers a promising treatment option for multifocal papillary thyroid cancer," Dr. Yu said. "Additionally, microwave ablation is associated with fewer complications and can preserve thyroid function, thereby enhancing patients' quality of life. This represents a significant advancement in the field of interventional thyroid cancer treatment."

Dr. Yu notes that microwave ablation does not routinely include preventative ablation of lymph nodes. In surgical resection, preventative lymph node removal is a common practice. However, the results provide the first evidence that even without lymph node ablation, microwave ablation yielded comparable survival rates to surgical resection.